CARM
Carisma Therapeutics Inc
$
0.270
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.2778
Open
0.277
VWAP
0.27
Vol
371.71K
Mkt Cap
11.28M
Low
0.2611
Amount
99.58K
EV/EBITDA(TTM)
--
Total Shares
41.54M
EV
9.63M
EV/OCF(TTM)
--
P/S(TTM)
1.05
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. The Company seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. It is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
3.75M
-59.23%
--
--
3.75M
+10.78%
--
--
3.77M
+3.23%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Carisma Therapeutics, Inc. (CARM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 39.90%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+39.90%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Carisma Therapeutics Inc (CARM.O) is -0.57, compared to its 5-year average forward P/E of -1.41. For a more detailed relative valuation and DCF analysis to assess Carisma Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.41
Current PE
-0.57
Overvalued PE
-0.56
Undervalued PE
-2.27
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
10.30
Current PS
1.02
Overvalued PS
23.86
Undervalued PS
-3.25
Financials
Annual
Quarterly
FY2025Q1
YoY :
+9.77%
3.73M
Total Revenue
FY2025Q1
YoY :
-52.16%
-9.33M
Operating Profit
FY2025Q1
YoY :
-51.18%
-9.27M
Net Income after Tax
FY2025Q1
YoY :
-52.17%
-0.22
EPS - Diluted
FY2025Q1
YoY :
-55.14%
-10.07M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-54.49%
-238.75
FCF Margin - %
FY2025Q1
YoY :
-55.52%
-248.48
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 425.33% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CARM News & Events
Events Timeline
2025-06-23 (ET)
2025-06-23
07:33:47
Carisma Therapeutics, OrthoCellix enter definitive merger agreement
2024-12-09 (ET)
2024-12-09
07:34:24
Carisma Therapeutics announces restructuring, 34% workforce reduction
2024-11-08 (ET)
2024-11-08
06:33:44
Carisma Therapeutics reports data from its CAR-M therapy
Sign Up For More Events
Sign Up For More Events
News
7.0
07-26GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNP on Behalf of Shareholders
7.0
07-16PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, CARM, HLGN on Behalf of Shareholders
7.0
07-05GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE, CARM, ENZB on Behalf of Shareholders
Sign Up For More News
People Also Watch
MIGI
Mawson Infrastructure Group Inc
0.420
USD
-4.55%
JFU
9F Inc
1.533
USD
-3.58%
ADN
Advent Technologies Holdings Inc
1.890
USD
-1.05%
BLIN
Bridgeline Digital Inc
1.480
USD
0.00%
IBO
Impact Biomedical Inc
0.585
USD
-0.51%
DFLI
Dragonfly Energy Holdings Corp
0.234
USD
-8.22%
PMNT
Perfect Moment Ltd
0.281
USD
+2.55%
MCVT
Mill City Ventures III Ltd
5.990
USD
-2.92%
FAQ
What is Carisma Therapeutics Inc (CARM) stock price today?
The current price of CARM is 0.27 USD — it has decreased -1.82 % in the last trading day.
What is Carisma Therapeutics Inc (CARM)'s business?
What is the price predicton of CARM Stock?
What is Carisma Therapeutics Inc (CARM)'s revenue for the last quarter?
What is Carisma Therapeutics Inc (CARM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Carisma Therapeutics Inc (CARM)'s fundamentals?
How many employees does Carisma Therapeutics Inc (CARM). have?